PTO-Form 1449

(Use several sheets if necessary)

O 1 P & 4 TION AF

ATTY DOCKET NO.

APPLICATION NO

42837-2001021

10/748,089

APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

GROUP

December 29, 2003

Not yet assigned

U.S. PATENT DOCUMENTS

EVALUNED	Γ	<u> </u>		,			FILING DAT
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIA
SNA	1	4,018,913	04/19/77	Okamoto, et al. (equiv to DE 2655636)	514	_28	
0	2.	4,018,915	04/19/77	Okamoto, et al. (equiv to DE 2655636)	514	20	
	3.	4,036,955	07/10/77	Okamoto, et al. (equiv to DE 2655636)	514	20	
	4.	4,041,156	08/09/77	Okamoto, et al. (equiv to DE 2655636)	514	w	
	5.	4,046,876	09/06/77	Okamoto, et al. (equiv to DE 2655636)	514	20	
	6.	4,055,651	10/25/77	Okamoto, et al. (equiv to DE 2655636)	514	319	
	7.	4,055,636	10/25/77	Okamoto, et al. (equiv to DE 2655636)	514	20	
	8.	4,070,457	01/24/78	Okamoto, et al. (equiv to DE 2655636)	514	510	
	9.	4,073,914	02/14/78	Kikumoto, et al. (equiv to DE 2655636)	514	319	
	10.	4,085,057	04/18/78	Masuda, et al.	430	108.21	
	11.	4,096,255	06/20/78	Kikumoto, et al. (equiv to DE 2655636)	514	227.5	
	12.	4,104,392	08/01/78	Okamoto, et al. (equiv to DE 2655636)	514	307	
	13.	4,438,122	03/20/84	Holmwood, et al.	514	277	
	14.	4,505,910	03/19/85	Bagli	514	26	
	15.	4,518,600	05/21/85	Holmwood, et al.	514	256	
	16.	4,544,402	10/01/85	Schnurbusch, et al.	504	232	
	17.	4,559,345	12/17/85	Gomarasca, et al.	514	275	
	18.	4,672,065	06/09/87	Spatz	314	255.06	5
	19.	4,908,368	03/13/90	Murase, et al.	514	25(
	20.	4,959,364	09/25/90	Mueller, et al.	514	237.5	
	21.	4,992,439	02/12/91	Meanwell	514	247	
	22.	5,030,644	07/09/91	Baldwin, et al.	514	343	
	23.	5,120,734	06/09/92	Klausener, et al.	514	252.63	
	24.	5,238,934	08/24/93	Knuppel, et al.	512	241	
	25.	5,278,184	01/11/94	Artico, et al.	514	423	
	26.	5,510,332	04/23/96	Kogan, et al.	514	14	
\$1	27.	5,580,868	12/03/96	Lunkenheimer, et al.	514	222.5	
N/	28.	5,770,573	06/23/98	Arrhenius, et al.	460	52	W
8°977	29.	5,814,643	09/29/98	Duggan, et al.	514	84	

July 1 2/16/01

PTO-Form 1449

(Use several sheets if necessary)

ATION FEB 17 2004 S

ATTY DOCKET NO. 42837-2001021

10/748.089

APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

GROUP

December 29, 2003

Not yet assigned

					Sheet 2 OI
1 'A 1/- 1	30.	5,861,429	01/19/99	Sato, et al.	514 456 -
2	31.	5,925,644	07/20/99	Jakobi, et al.	314 264
	32.	5,942,504	08/24/99	Grobelny.	514 218
	33.	5,955,491	09/21/99	Sohda, et al.	514 215
	34.	5,962,479	10/05/99	Chen	514 348
	35.	5,972,946	10/26/99	Murata, et al.	514 256
	36.	6,005,117	12/21/99	Wehner, et al.	514 332.5
77	37.	2002/0052375	05/02/02	Konradi, et al.	514 252.68
	38.	2002/0055509	05/09/02	Konradi, et al.	514 248
8,7	39.	2003/0144328	07/31/03	Konradi, et al.	514 365 -V

FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO Canada 40. 07/03/77 2,241,149 (equiv to DE 19548709) Canada 41. 2,259,224 01/08/78 (equiv to DE 19654483) 42. 0 116 494 08/1984 Europe 43. 0 147 211 07/03/93 Europe 44. 0 288 176 10/26/88 Europe 45. 0 330 506 A2 08/30/89 Europe 46. 0 330 506 A3 08/30/89 Europe 47. 0 526 348 02/03/93 Europe 48. 0 535 521 04/07/93 Europe Germany 49. 19548709 07/03/97 (equiv to CA 2,241,149) 50. 19536891 04/1997 Germany Germany 51. 19654483 01/02/98 (equiv to CA 2,259,224) 52. 19713000 10/01/98 Germany (Abstract) Germany 53. (US equiv are all Okamoto and Kikumoto 2655636 06/23/77 US patents listed above) **Great Britain** 54. 1500063 02/08/78 (equiv to HU 169926) Hungary 55. 169926 09/28/76 (equiv to GB 150063) 56. 59212480 12/1984 Japan (Abstract) **5**7. 92/16549 10/01/92 **WIPO 58.** 93/12809 07/08/93 WIPO 59. 96/01644 01/25/96 **WIPO**

Jul 12/04

PTO-Form 1449	
INFORMATIOI (Use se	N DISCLOSURE CITATION Coveral sheets if necessary) FEB 1 7 2004 (C)

ATTY DOCKET NO.

APPLICATION NO

42837-2001021

10/748,089

APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

GROUP

December 29, 2003

Not yet assigned

0 /							Shee	13 of 5
Ne	60.	96/22966	08/01/96	WIPO			1	
	61.	96/32383	04/1997	WIPO	<u> </u>			
	62.	97/23451	07/03/97	WIPO	<u> </u>			
	63.	98/00395	01/08/98	WIPO			<u> </u>	
	64.	98/33783	12/03/98	WIPO				
	65.	98/53814	12/03/98	WIPO (Abstract)				
	66.	98/53817	08/06/98	WIPO			↓ [
	67.	99/06431	02/11/99	WIPO			<u> </u>	
	68.	99/06432	02/11/99	WIPO			<u> </u>	
	69.	99/06433	02/11/99	WIPO				
	70.	99/06390	02/11/99	WIPO			11	
	71.	99/06391	02/11/99	WIPO				
	72.	99/10312	03/04/99	WIPO				
	73.	99/10313	03/04/99	WIPO				
7	74.	99/37605	07/29/99	WIPO				
	75.	99/37618	07/29/99	WIPO		1 1	14	41
	76.	99/52898	10/21/99	WIPO		1	<u> </u>	N

,		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
80	177.	Abraham, et al. "Alpha4-Integrins Mediate Antigen-Induced Late Bronchial Responses and Prolonges Airway Hyperresponsiveness in Sheep," <i>J. Clin. Invest.</i> 93: 776-787 (1994).
9	78.	Advani, S.B., et al. "Potential Antineoplastic Agents: N-(1-Benzoxazolyl)amino Acid Esters," <i>J. Pharm. Sci.</i> 57(10): 1693-1696 (1968).
	79.	Bao, et al. "Correlation of VLA-4 Integrin Expression with Metastatic Potential in Various Human Tumor Cell Lines," Diff. 52: 239-246 (1993).
	80.	Baron, et al. "Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma," <i>J. Exp. Med.</i> 177: 57-68 (1993).
	81.	Baron, et al. "The Pathogensis of Adoptive Murine Autoimmune Diabetes Requires an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1," <i>J. Clin. Invest.</i> 93: 1700-1708 (1994).
	82.	Burkly, et al. "Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigen-4 Integrin," <i>Diabetes</i> 43: 529-534 (1994).
	83.	Cybulsky, et al. "Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule during Atherogenesis," Science 251: 788-791 (1991).
	84.	Elices, et al. "Expression and Functional Significance of Alternatively Spliced CS1 Fibronectin in Rhematoid Arthritis Microvasculature," <i>J. Clin. Invest.</i> 93: 405-416 (1994).
	85.	Elices, et al. "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrim VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site," Cell 60: 577-584 (1990).
	86.	Gordeev, M.F., et al. "Combinatorial Approaches to Pharmacophoric Heterocycles: A Solid-Phase Synthesis of 3,1-Benzoxazine-4-ones," "Biotech. And Bioengineering 61(1): 13-16 (1998).
77	87.	Hamann, et al. "Role of α4-Integrins in Lymphocyte Homing to Mucosal Tissues <i>In Vivo</i> ," <i>J. Immunol</i> . 152: 3283-3292 (1994).
878	88.	Henke, B.R., et al. "N-(2-Benzoylphenyl)-L-tyrosine: Aryl Agonists. Disclovery of a Novel Series of Potent Antihyperglycemic and Antihyperglipidemic Agents." J. Med. Chem. 41(25): 5020-5036 (1998).

Suntah Blood 3/2

2/26/0M

PT	റ-	Fοι	m	14	149

INFORMATION DISCLOSURE CHATION (Use several sheets if necessary) FEB 1 7 2004 ATTY DOCKET NO. 42837-2001021 APPLICATION NO 10/748,089

APPLICANT

Andrei W. KONRADI, et al.

FILING DATE

GROUP

December 29, 2003

Not yet assigned

		Sheet 4 of 5
Sand I	§ 9.	Hladon, B., et al. "In Vitro cytostatic activity of some amino acid 4-N-substitied cytosines," Arch. Immunol. Ther. Exp. 40(2): 145-150 (1992 (Abstract)
	90.	Hoffman, S., et al. "N-Pyrimidinylamino acids, III. N-(oxopyrimidinyl) derivatives of neutral amino acids, Z. Chem. 12(1): 21-22 (1972). CODEN: ZEACEAL. (Abstract).
	91.	Jaeger, et al. <i>Chem. Berichte</i> . 101(8): 2762-2770 (1968). Chem. Abstract 69: 676 Kawaguchi, et al. "VLA-4 Molecules on Tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface," <i>Jap. J. Canc. Res.</i> 83: 1304-1316 (1992).
	92.	Lauri, et al. "Decreased Adhesion to Endothelial Cells and Matrix of H-2k ^b Gene Transfected Tumor Cells," <i>Br. J. Canc.</i> 68: 862-867 (1993).
	93.	Lazer, E. S., et al. "Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action," <i>J. Med. Chem.</i> 37(7): 913-923 (1994).
	94.	Li, et al. "An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leukocyte Adhesion Molecule in Rabbit Aortic Endothelium," <i>Arterioscir. Thromb.</i> 13: 197-204 (1993).
	95.	Ma, D., et al. "Accelerating Effect Induced by the Structure of α-Amino Acid in the Copper Catalyzed Coupling Reaction of Aryl Halides with α-Amino Acids. Synthesis of Benzolactam-V8," <i>J. Am. Chem.</i> Soc. 120(48): 12459-12467 (1998).
	96.	Marr-Leisy, et al. Colloid and Polymer Sc. 263(10): 791-798 (1985). Chem. Abstract 105: 97885
	97.	Mulligan, et al. "Role of β1, β1 Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes," <i>Immunology</i> 150: 2407-2417 (1993).
	98.	Ohta, et al. Heterocycles 31(9): 1655-1662 (1990). Chem. Abstract 114: 101454-1991:101454
	99.	Ohta, et al. <i>Chem. & Pharmaceutical Bulletin</i> 27(12): 2980-2987 (1979). Chem. Abstract 93: 46584-1980: 446584
	100.	Okahara, et al. "Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1 (VCAM-1) in Tumor Necrosis Factor a Enhancement of Experimental Metastasis," Can. Res. 54: 3233-3236 (1994).
	101.	Osborn. "Leukocyte Adhesion to Endothelium in Inflammation," Cell 62: 3-6 (1990).
	102.	Paavonen, et al. "In Vivo Evidence of the Role fo α4β1-VCAM-1 Interaction in Sarcoma, but not in Carcinoma Extravasation," Int. J. Can. 58: 298-302 (1994).
	103.	Paul, et al. "Monoclonal Antibodies Against LFA-1 and VLA-4 Inhibit Graft Vasculitis in Rat Cardiac Allografts," <i>Transpl. Proceed.</i> 25: 813-814 (1993).
	104.	Postigo, et al. "Increased Binding of Synovial T-Lynmphocytes from Rheumatoid Arthritis to Endothelial-Leukocyte Adhesion Molecule-1 (ELAN-1) and Vascular Cell Adhesion Molecule-1 (VCAM-1)," J. Clin. Invest. 89: 1445-1452 (1992).
	105.	Pretolani, et al. "Antibody to Very Late Activation Antigen 4 Prevents Antigen-induced Bronchial Hyperreactivity and Cellular Infiltration in the Guinea Pig Airways," J. Exp. Med. 180: 795-805 (1994).
	106.	Sasseville, et al. "Monocyte Adhesion to Endothelium in Simian Immunodeficiency Virus-Induced AIDS Encephalitis is Mediated by Vascular Cell Adhesion Molecule-1/α4β1 Integrin Interactions," <i>Am. J. Path.</i> 144: 27 (1994).
	107.	Schadendorf, et al. "Tumor Progression and Metastatic Behavior <i>In Vivo</i> Correlates with Integrin Expression in Melanocytic Tumores," <i>J. Path.</i> 170: 429-434 (1993).
	108.	Simchowitz, et al. <i>J. Biol. Chem.</i> 265(23): 13457-13463-1990:530558
	109.	Springer, et al. "Adhesion Receptors of the Immune System," Nature. 346: 425-434 (1990).
	110.	Teranishi, K., et al. "Synthesis and Chemiluminescense of Coelenterazine (Oplophorus Luciferin) Analogs," Bull. Chem. Soc., Jpn. 63(11): 3132-3140 (1990).
7	111. Oc	van Dinther-Janssen, et al. "Role of the CS1 Adhesion Motif of Fibronectin in T Cell Ahesion to Synovial Membrane and Peripheral Lymph Node Endothelium," <i>Annals. Rheumatic Dis.</i> 52: 672-676 (1993).
800	A 22,	van Dinther-Janssen, et al. "The VLA-4/VCAM-1 Pathway is Involved in Lymphocyte Adhesion to Endothelium in Theumatoid Synovium," <i>J. Immunology</i> . 147: 4207-4210 (1991).

PTO-Form 1449 ATTY DOCKET NO. APPLICATION NO 10/748,089 42837-2001021 INFORMATION DISCLOSURE CITADON APPLICANT (Use several sheets if necessary) Andrei W. KONRADI, et al. FEB 1 7 2004 GROUP FILING DATE December 29, 2003 Not yet assigned Sheet 5 of 5 Vedder, et al. "Role of Neutrophils in Generalized Reperfusion Injury Associted with Resuscitation 113. from Shock," Surgery 106: 509-516 (1989). Yang, et al. "Inhibition of Insultitis and Prevention of Diabetes in Nonobese Diabetic Mice by Blocking L-Selectin and Very Late Antigen 4 Adhesion Recptors," Proc. Natl. Acad. Sci. (USA) 90: 10494-

EXAMINER \

115.

DATE CONSIDERED

Yednock, et al. "Prevention of Experimental Autommune Encephalomyelitis by Antibodies Against

7/26/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

α4β1 Integrin," Nature 356: 63-66 (1992).